COMMUNIQUÉS West-GlobeNewswire
-
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
06/11/2025 -
Porch Light Health Launches Advanced Drug Lab to Improve Patient Safety and Spot Dangerous Drug Trends in Our Communities
06/11/2025 -
Pennant Group to Participate in the 2025 Stephens Annual Investment Conference
06/11/2025 -
PharmaCorp Announces Upsized C$20 Million Bought Deal Public Offering
06/11/2025 -
Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform
06/11/2025 -
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
06/11/2025 -
Consortium consisting of Nordic Capital and Permira announces preliminary result of the takeover offer to shareholders of Bavarian Nordic and that the Offer is withdrawn and will not be completed
06/11/2025 -
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
06/11/2025 -
MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
06/11/2025 -
Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation
06/11/2025 -
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
06/11/2025 -
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences
06/11/2025 -
SS Innovations Announces Successful Completion of First Telesurgery Performed with the Company’s SSi Mantra Tele Surgeon Console
06/11/2025 -
Vivos Inc. Issues Shareholder Update Letter
06/11/2025 -
Sienna Expands Retirement Portfolio in Key Ontario Market
06/11/2025 -
PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
06/11/2025 -
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results
06/11/2025 -
RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD
06/11/2025 -
Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update
06/11/2025
Pages
Other news
The growth capital will expand manufacturing capacity, reduce backlog, and support new regulatory filings
WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp.
BreathiZen is a once-daily oral spray that brings together botanical extracts, an enzyme preparation, and selected nutrients in a 60 ml bottle designed to fit easily into an adult wellness routine.
New York, Oct. 22, 2026 (GLOBE NEWSWIRE) --
Company to host conference call on November 5, 2026, at 4:30 p.m. ET
PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc.
Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation
TEL AVIV, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc.